Over the past five years, Regeneron Pharmaceuticals' (NASDAQ:REGN) stock has consistently outperformed its underlying earnings growth. However, recent insider selling of around US$26m potentially signals greater hesitancy. Despite volatile days and competition, Regeneron stocks have generally held their ground.
The company is under investigation by multiple law firms including the Portnoy Law Firm and Pomerantz Law Firm, which have raised concerns over potential shareholder claims. However, these developments have not halted its upward progress, with the company receiving an upgraded price target of $1,182.00 from Morgan Stanley, and reaching new 52-week highs.
Various heavyweight investors including Norden Group LLC and Jennison Associates LLC have significantly increased their holdings. At the same time, Regeneron has received regulatory approval for their Lymphoma drug and is collaborating with Mammoth on gene-editing therapies. One negative mark in an otherwise strong quarter includes weaker sales posted for its blockbuster eye drug due to inventory issues.
Regeneron Pharmaceuticals REGN News Analytics from Fri, 22 Dec 2023 08:00:00 GMT to Sun, 14 Jul 2024 14:41:39 GMT - Rating 4 - Innovation 6 - Information 7.5 - Rumor -1
